Table 1.
Clinical characteristics of CLI patients treated with or without sarpogrelate
| Patients with sarpogrelate (n = 67) | Patients without sarpogrelate | ||
|---|---|---|---|
| Overall (n = 319) | Matched controls (n = 67) | ||
| Male | 40 (60 %) | 217 (68 %) | 45 (67 %) |
| Age (years) | 71 ± 14 | 71 ± 10 | 71 ± 11 |
| Body mass index (kg/m2) | 21.0 ± 3.2 | 21.4 ± 3.2 | 21.0 ± 2.7 |
| Nonambulatory state | 21 (31 %) | 134 (42 %) | 24 (36 %) |
| Fontaine stage IV | 57 (85 %) | 258 (81 %) | 59 (88 %) |
| Infection | 15 (22 %) | 68 (21 %) | 16 (24 %) |
| Revascularization procedures | |||
| Stent use | 28 (42 %) | 159 (50 %) | 30 (45 %) |
| Self-expanding stent | 27 (96 %) | 136 (86 %) | 29 (97 %) |
| Infrapopliteal revascularization | 45 (67 %) | 228 (71 %) | 46 (69 %) |
| Comorbidities | |||
| Coronary artery disease | 21 (31 %) | 115 (36 %) | 29 (43 %) |
| Cerebrovascular disease | 20 (30 %) | 105 (33 %) | 17 (25 %) |
| Diabetes mellitus | 41 (61 %) | 239 (75 %)* | 47 (70 %) |
| Hypertension | 60 (90 %) | 272 (85 %) | 60 (90 %) |
| Dyslipidemia | 49 (73 %) | 246 (77 %) | 53 (79 %) |
| Smoking | 39 (58 %) | 188 (59 %) | 42 (63 %) |
| Hemodialysis | 29 (43 %) | 147 (46 %) | 27 (40 %) |
| Antiplatelet therapy | |||
| Aspirin | 55 (82 %) | 282 (88 %) | 56 (84 %) |
| Thienopyridines | 17 (25 %) | 113 (35 %) | 18 (27 %) |
| Cilostazol | 29 (43 %) | 200 (63 %)* | 33 (49 %) |
| More than one agent | 36 (54 %) | 220 (69 %)* | 40 (60 %) |
Data are mean ± standard deviation or n (%)
* P < 0.05 compared with patients treated with sarpogrelate